licensing

News

Abstract blue DNA background. Medicine concept. 3D Rendering

Biogen teams up with gene-editing startup Scribe on ALS prog...

Scribe Therapeutics, a start-up focusing on gene-editing using CRISPR/Cas9, has burst onto the biotech scene with a $415 million deal with Biogen.

News

AZ buys oral PCSK9 cholesterol drug from Dogma Therapeutics

AstraZeneca has bought rights to an orally-active drug that inhibits PCSK9, offering a patient-friendly alternative to current cholesterol-lowering therapies that have to be delivered via a

News

Exelixis doubles down on ADCs for cancer with NBE, Catalent ...

Exelixis made its name developing small-molecule drugs for cancer, so a new pair of deals focused on antibody-drug conjugates reinforces a recent change of direction for the biotech.

News

AbbVie signs $2.9bn deal with I-Mab for ‘don’t eat me’ cance...

AbbVie has claimed rights to an immuno-oncology antibody from I-Mab in what is thought to be a record licensing deal involving a Chinese biotech.

News

Latecomer Lilly throws cash at Innovent PD-1 partnership

Eli Lilly has doubled down on its partnership with Chia’s Innovent with a licensing deal for ex-China rights to Tyvyt, their PD-1 inhibitor, which some analysts think may be la

News

Concept of memory loss and brain aging due to dementia and alzheimer's disease as a medical icon with fall trees shaped as a human head losing leaves with 3D illustration elements.

Roche doubles down on tau for Alzheimer’s, licensing UCB dru...

Roche already has one Alzheimer’s candidate in its pipeline targeting tau, but has added a second via a deal with Belgian drugmaker UCB worth up to $2 billion.

Biogen teams up with gene-editing startup Scribe on ALS prog...

AZ buys oral PCSK9 cholesterol drug from Dogma Therapeutics

Exelixis doubles down on ADCs for cancer with NBE, Catalent ...

AbbVie signs $2.9bn deal with I-Mab for ‘don’t eat me’ cance...

Latecomer Lilly throws cash at Innovent PD-1 partnership

Roche doubles down on tau for Alzheimer’s, licensing UCB dru...

Threat of Trump's pharma tariffs looms again

Using AI-driven synthetic personas to take your insights fur...

licensing

Editor's Picks